Zobrazeno 1 - 9
of 9
pro vyhledávání: '"35"'
Autor:
Mark J. Ratain, Arlene A. Forastiere, Lei Ye, Robert F. Gagel, Ezra E.W. Cohen, Linda Janisch, Steven I. Sherman, Forlisa Nauling, David S. Hong, Chaan S. Ng, Razelle Kurzrock, Thomas Müller, Ranee Mehra, Douglas W. Ball, John W. Frye, David G. Pfister, Roger B. Cohen, Ravi Salgia
Publikováno v:
Journal of Clinical Oncology. 29:2660-2666
Purpose XL184 (cabozantinib) is a potent inhibitor of MET, vascular endothelial growth factor receptor 2 (VEGFR2), and RET, with robust antiangiogenic, antitumor, and anti-invasive effects in preclinical models. Early observations of clinical benefit
Autor:
Moacyr Ribeiro de Oliveira, D. Ross Camidge, Elizabeth Litvinovich, Yi-Lin Chiu, Cathy E. Nolan, Charles M. Rudin, Divis Khaira, Geoffrey I. Shapiro, Todd A. Busman, Hao Xiong, Caroline Dive, David R. Gandara, Evelyn McKeegan, Philip Bonomi, Sari H. Enschede, Rod A. Humerickhouse, Andrew Krivoshik, Leena Gandhi, Philip M. Hemken, Christine L. Hann
Publikováno v:
Journal of Clinical Oncology. 29:909-916
Purpose Resistance to chemotherapy-induced apoptosis represents a major obstacle to cancer control. Overexpression of Bcl-2 is seen in multiple tumor types and targeting Bcl-2 may provide therapeutic benefit. A phase I study of navitoclax, a novel in
Autor:
Li-An Xu, Thomas J. Lynch, Lowell L. Hart, Christopher T. Harbison, Christine Horak, Robert C. Hermann, Shaker R. Dakhil, Melissa Awad, Shirin Khambata-Ford, Martin R. Weber
Publikováno v:
Journal of Clinical Oncology. 28:918-927
Purpose The anti–epidermal growth factor receptor (EGFR) antibody cetuximab is efficacious in multiple tumor types. Patient selection with markers predictive of benefit may enhance its therapeutic index. This retrospective, correlative analysis of
Autor:
Suzanne Berlin, Hang Lee, Neil S. Horowitz, Ursula A. Matulonis, Richard T. Penson, Modjulie A. King, Carolyn N. Krasner, Stephen A. Cannistra, Paul DiSilvestro, Don S. Dizon, Maria R. Roche, Susana M. Campos
Publikováno v:
Journal of Clinical Oncology. 28:154-159
Purpose New strategies are needed to improve outcomes for patients with advanced ovarian cancer. Bevacizumab is a recombinant humanized monoclonal antibody that neutralizes vascular endothelial growth factor but is associated with GI perforations (GI
Autor:
Dennis F. Moore, Primo N. Lara, Zelanna Goldberg, Quynh-Thu Le, John Crowley, James J. Moon, Mary W. Redman, Laurie E. Gaspar, Stephen K. Williamson, David R. Gandara
Publikováno v:
Journal of Clinical Oncology. 27:3014-3019
Purpose A SWOG pilot study (S0004) showed that tirapazamine (TPZ) when combined with concurrent chemoradiotherapy yielded a promising median survival of 22 months in limited-stage small-cell lung cancer (LSCLC). We report results of the phase II stud
Autor:
Chuan-beng Chen, Gang Xu, Jianji Pan, Shan-wen Zhang, Dongming Li, You-yong Lü, Xing Su, Chang-qin Liu, Shaowen Xiao, Bo Xu, Yan Sun
Publikováno v:
Journal of Clinical Oncology. 27:799-804
Purpose To centrally assess the safety, efficacy, and 6-year follow-up of recombinant adenovirus-p53 (rAd-p53) combined with radiotherapy (RT) for patients with nasopharyngeal carcinoma (NPC). Patients and Methods A randomized controlled clinical stu
Publikováno v:
Journal of Clinical Oncology. 27:334-343
Purpose Most studies on postcancer reproduction are limited in patient numbers and lack of control group. We have computed 10-year first postdiagnosis cumulative reproduction rates (10-PDRs) and hazard ratios (HRs) avoiding these limitations. Patient
Autor:
M. R. Cooper, Karen H. Antman, Mark R. Green, Nicholas J. Vogelzang, James E. Herndon, Joseph M. Corson, L B Weissman
Publikováno v:
Journal of Clinical Oncology. 12:1436-1442
PURPOSE Folic acid antagonists are reported to have activity against mesothelioma. The Cancer and Leukemia Group B (CALGB) undertook this phase II study of the new antifolate, trimetrexate (TMTX), to evaluate its response rate and toxicity in chemoth
Autor:
J Kinzie, Arnold Herskovic, P B Lattin, E Tapazoglou, C G Leichman, Z Steiger, J.C. Rosenberg, A Arbulu, I. Asfaw, L Leichman
Publikováno v:
Journal of Clinical Oncology. 5:365-370
Based on the surgical pathology and survival for patients in previous trials using a neoadjuvant program of chemotherapy (5-fluorouracil [5-FU]-cisplatin) and radiation (3,000 cGy) before surgery for squamous-cell cancer (SCC) of the esophagus, a non